Orphazyme: Milestone reached in ALS
Research Note
2019-07-18
12:19
Earlier today, Orphazyme announced that they have completed enrollment in the phase III program with arimoclomol in Amyotrophic Lateral Sclerosis (ALS). It means that it is on track to present top-line results in H1’21.
AH
Anders Hedlund
Disclosures and disclaimers